Cardiovascular risk and the omega-3 index.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion without new empirical data or systematic review methodology
PubMed 17876200 · doi:10.2459/01.JCM.0000289273.87803.87
What was done
This narrative review summarizes evidence supporting the clinical use of the omega-3 index—defined as the combined percentage of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell membranes—as a standardized biomarker for sudden cardiac death (SCD) risk assessment and therapeutic monitoring.
What was found
The review highlights epidemiological findings showing a steep risk reduction for SCD between an omega-3 index of 3.3% (relative risk 1.0) and 6.5% (relative risk 0.1). The authors note that EPA and DHA demonstrate antiarrhythmic effects at supraventricular and ventricular levels.
Why it matters
It promotes red blood cell membrane EPA+DHA percentage as a standardized, modifiable biomarker for stratifying SCD risk and guiding dietary or therapeutic interventions.
Limits
The abstract describes a narrative review and expert proposal rather than an original empirical study or systematic review. No confidence intervals, sample sizes, or baseline cohort characteristics are provided.
Cited by
- supports People with an omega-3 index of 8% or higher had a 90% lower risk of sudden cardiac death compared to those with an index of 4% or below.